Cargando…
Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
CONTEXT: Hyperglucagonemia may develop in type 2 diabetes due to obesity-prone hepatic steatosis (glucagon resistance). Markers of glucagon resistance (including the glucagon-alanine index) improve following diet-induced weight loss, but the partial contribution of lowering hepatic steatosis vs body...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561012/ https://www.ncbi.nlm.nih.gov/pubmed/37818402 http://dx.doi.org/10.1210/jendso/bvad122 |
_version_ | 1785117832175943680 |
---|---|
author | Kjeldsen, Sasha A S Thomsen, Mads N Skytte, Mads J Samkani, Amirsalar Richter, Michael M Frystyk, Jan Magkos, Faidon Hansen, Elizaveta Thomsen, Henrik S Holst, Jens J Madsbad, Sten Haugaard, Steen B Krarup, Thure Wewer Albrechtsen, Nicolai J |
author_facet | Kjeldsen, Sasha A S Thomsen, Mads N Skytte, Mads J Samkani, Amirsalar Richter, Michael M Frystyk, Jan Magkos, Faidon Hansen, Elizaveta Thomsen, Henrik S Holst, Jens J Madsbad, Sten Haugaard, Steen B Krarup, Thure Wewer Albrechtsen, Nicolai J |
author_sort | Kjeldsen, Sasha A S |
collection | PubMed |
description | CONTEXT: Hyperglucagonemia may develop in type 2 diabetes due to obesity-prone hepatic steatosis (glucagon resistance). Markers of glucagon resistance (including the glucagon-alanine index) improve following diet-induced weight loss, but the partial contribution of lowering hepatic steatosis vs body weight is unknown. OBJECTIVE: This work aimed to investigate the dependency of body weight loss following a reduction in hepatic steatosis on markers of glucagon resistance in type 2 diabetes. METHODS: A post hoc analysis was conducted from 2 previously published randomized controlled trials. We investigated the effect of weight maintenance (study 1: isocaloric feeding) or weight loss (study 2: hypocaloric feeding), both of which induced reductions in hepatic steatosis, on markers of glucagon sensitivity, including the glucagon-alanine index measured using a validated enzyme-linked immunosorbent assay and metabolomics in 94 individuals (n = 28 in study 1; n = 66 in study 2). Individuals with overweight or obesity with type 2 diabetes were randomly assigned to a 6-week conventional diabetes (CD) or carbohydrate-reduced high-protein (CRHP) diet within both isocaloric and hypocaloric feeding-interventions. RESULTS: By design, weight loss was greater after hypocaloric compared to isocaloric feeding, but both diets caused similar reductions in hepatic steatosis, allowing us to investigate the effect of reducing hepatic steatosis with or without a clinically relevant weight loss on markers of glucagon resistance. The glucagon-alanine index improved following hypocaloric, but not isocaloric, feeding, independently of macronutrient composition. CONCLUSION: Improvements in glucagon resistance may depend on body weight loss in patients with type 2 diabetes. |
format | Online Article Text |
id | pubmed-10561012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105610122023-10-10 Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes Kjeldsen, Sasha A S Thomsen, Mads N Skytte, Mads J Samkani, Amirsalar Richter, Michael M Frystyk, Jan Magkos, Faidon Hansen, Elizaveta Thomsen, Henrik S Holst, Jens J Madsbad, Sten Haugaard, Steen B Krarup, Thure Wewer Albrechtsen, Nicolai J J Endocr Soc Clinical Research Article CONTEXT: Hyperglucagonemia may develop in type 2 diabetes due to obesity-prone hepatic steatosis (glucagon resistance). Markers of glucagon resistance (including the glucagon-alanine index) improve following diet-induced weight loss, but the partial contribution of lowering hepatic steatosis vs body weight is unknown. OBJECTIVE: This work aimed to investigate the dependency of body weight loss following a reduction in hepatic steatosis on markers of glucagon resistance in type 2 diabetes. METHODS: A post hoc analysis was conducted from 2 previously published randomized controlled trials. We investigated the effect of weight maintenance (study 1: isocaloric feeding) or weight loss (study 2: hypocaloric feeding), both of which induced reductions in hepatic steatosis, on markers of glucagon sensitivity, including the glucagon-alanine index measured using a validated enzyme-linked immunosorbent assay and metabolomics in 94 individuals (n = 28 in study 1; n = 66 in study 2). Individuals with overweight or obesity with type 2 diabetes were randomly assigned to a 6-week conventional diabetes (CD) or carbohydrate-reduced high-protein (CRHP) diet within both isocaloric and hypocaloric feeding-interventions. RESULTS: By design, weight loss was greater after hypocaloric compared to isocaloric feeding, but both diets caused similar reductions in hepatic steatosis, allowing us to investigate the effect of reducing hepatic steatosis with or without a clinically relevant weight loss on markers of glucagon resistance. The glucagon-alanine index improved following hypocaloric, but not isocaloric, feeding, independently of macronutrient composition. CONCLUSION: Improvements in glucagon resistance may depend on body weight loss in patients with type 2 diabetes. Oxford University Press 2023-09-21 /pmc/articles/PMC10561012/ /pubmed/37818402 http://dx.doi.org/10.1210/jendso/bvad122 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Article Kjeldsen, Sasha A S Thomsen, Mads N Skytte, Mads J Samkani, Amirsalar Richter, Michael M Frystyk, Jan Magkos, Faidon Hansen, Elizaveta Thomsen, Henrik S Holst, Jens J Madsbad, Sten Haugaard, Steen B Krarup, Thure Wewer Albrechtsen, Nicolai J Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes |
title | Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes |
title_full | Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes |
title_fullStr | Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes |
title_full_unstemmed | Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes |
title_short | Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes |
title_sort | markers of glucagon resistance improve with reductions in hepatic steatosis and body weight in type 2 diabetes |
topic | Clinical Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561012/ https://www.ncbi.nlm.nih.gov/pubmed/37818402 http://dx.doi.org/10.1210/jendso/bvad122 |
work_keys_str_mv | AT kjeldsensashaas markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT thomsenmadsn markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT skyttemadsj markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT samkaniamirsalar markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT richtermichaelm markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT frystykjan markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT magkosfaidon markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT hansenelizaveta markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT thomsenhenriks markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT holstjensj markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT madsbadsten markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT haugaardsteenb markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT krarupthure markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes AT weweralbrechtsennicolaij markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes |